A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Public ClinicalTrials.gov record NCT06976268. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants With Early Parkinson's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.
Study identification
- NCT ID
- NCT06976268
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 550 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 27, 2025
- Primary completion
- Jul 31, 2027
- Completion
- Aug 31, 2028
- Last update posted
- Aug 25, 2026
2025 – 2028
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site-049 | Birmingham | Alabama | 35294 | Recruiting |
| Site-041 | Los Angeles | California | 90033 | Recruiting |
| Site-025 | Aurora | Colorado | 80045 | Recruiting |
| Site-031 | Farmington | Connecticut | 06030 | Recruiting |
| Site-028 | New Haven | Connecticut | 06510 | Recruiting |
| Site-038 | Atlantis | Florida | 33462 | Recruiting |
| Site-017 | Boca Raton | Florida | 33486 | Recruiting |
| Site-051 | Maitland | Florida | 32751 | Recruiting |
| Site-027 | Chicago | Illinois | 60611 | Recruiting |
| Site-071 | Boston | Massachusetts | 02114 | Recruiting |
| Site-015 | Farmington Hills | Michigan | 48334 | Recruiting |
| Site-044 | Chesterfield | Missouri | 63005 | Recruiting |
| Site-006 | Albany | New York | 12208 | Recruiting |
| Site-005 | New York | New York | 10021 | Recruiting |
| Site-091 | Portland | Oregon | 97210 | Recruiting |
| Site-043 | Round Rock | Texas | 78681 | Recruiting |
| Site-074 | Newport News | Virginia | 23601 | Recruiting |
| Site-007 | Bellevue | Washington | 98007 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06976268, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 25, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06976268 live on ClinicalTrials.gov.